HT-29

HT-29 is a human colon cancer cell line used extensively in biological and cancer research.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

HT-29 is a human colon cancer cell line used extensively in biological and cancer research.

Characteristics

The HT-29 cell line was established in 19641 from the tumor of a 44-year-old Caucasian female with colorectal adenocarcinoma by Dr. Jorgen Fogh at the Memorial Sloan Kettering Cancer Center. HT-29 cells grow in a tight monolayer and share similar features with small intestinal enterocytes.

Under specific conditions, such as glucose deprivation or exposure to differentiation-inducing agents like sodium butyrate, these cells develop epithelial cell morphology, characterized by microvilli and well-defined tight junctions.

Genetic characteristics and mutations

HT-29 cells carry several genetic alterations common in colorectal carcinomas, most notably mutations in the tumor suppressor genes TP53 and APC, and in the oncogene BRAF. Specifically, HT-29 cells overproduce the p53 tumor antigen, but have a mutation in the p53 gene at position 273, resulting in a histidine replacing an arginine.

This mutation is associated with altered tumor suppressor functions, increased cellular proliferation, and resistance to apoptosis. HT-29 cells also exhibit deregulated expression of the c-myc oncogene.

Although deregulated, c-myc expression is closely linked with their responsiveness to growth factors and nutrient availability, suggesting a connection between oncogenic signaling pathways and their proliferative capacity. The BRAF V600E mutation in these cells constantly activates the MAP kinase signaling pathway.

This further contributes to cellular proliferation, survival, and resistance to various therapeutic agents. Overall, these characteristics make HT-29 cells a valuable model for studying colorectal cancer pathogenesis and treatment strategies.

Differentiation

HT-29 cells do not spontaneously differentiate under standard culture conditions. However, their differentiation into enterocyte-like cells can be induced through specific culture modifications or chemical treatments, allowing them to better replicate intestinal epithelial physiology.

Common approaches to induce HT-29 differentiation include: Glucose deprivation: Culturing in glucose-limited medium (~1 g/L glucose) prompts HT-29 cells to differentiate into polarized enterocyte-like cells. Under these conditions, cells exhibit tighter junctions, an apical brush border with microvilli, and express typical intestinal enzymes.

Sodium Butyrate Treatment: Treatment with sodium butyrate (2-5 mM) stimulates differentiation that causes increased expression of intestinal brush-border enzymes, polarization, and microvilli formation. This model mimics the differentiated features of mature colonic epithelial cells.

Methotrexate (MTX) Selection: Treatment with methotrexate selects a mucus-secreting subpopulation known as HT29-MTX. These cells differentiate into columnar, mucus-producing epithelial cells. This subpopulation can be a valuable model for studying intestinal barrier functions, mucosal biology, and interactions with microbiota.

These differentiation methods allow researchers to adapt HT-29 cells to study gastrointestinal physiology, pharmaceutical research, and microbiomes.

Cryopreservation

Proper cryopreservation allows for the long-term storage of HT-29 cells, ensuring their availability and genetic stability for ongoing research. It is important to optimize cryopreservation to maximize cell viability upon thawing. HT-29 cells are cryopreserved using a freezing medium consisting of 90% fetal bovine serum and 10% dimethyl sulfoxide (DMSO).

DMSO is a cryoprotectant to minimize ice crystal formation and cellular damage during freezing. Cells should be slowly frozen at a controlled rate (~1°C per minute), typically using a controlled-rate freezing apparatus or an isopropanol-based container. One frozen, cells are stored in liquid nitrogen at -196°C.

Xenograft models

HT-29 cells can also be tested in vivo via xenografts in immunodeficient rodents. These models are useful for investigating tumor growth, epithelial function, and pharmacokinetics in a controlled and biologically relevant environment.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369835309 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “HT-29” revision 1369835309 · retrieved 2026-10-20 date of establishment (×1) · confidence 0.95 revision URL